Go back
Title: Liver Directed Therapies in metastasis from Neuroendocrine Tumors
e-poster Number: EPOS 21
Category: e Poster
Author Name: Dr. Anand Agrawal
Institute:
Co-Author Name:
Abstract :
Introduction: This abstract delves into the critical aspect of response evaluation for liver-directed therapies in patients with liver metastases originating from neuroendocrine tumors (NET). By scrutinizing treatment outcomes and response rates, we aim to enhance our understanding of the efficacy of such therapies in managing NET-related liver metastasis.
Aims/objectives: To know the effect of liver directed therapy on hepatic progression free survival and overall survival.
Material/methods: The records of patients with NET and liver metastasis managed at our intitute. Forty-four patients were included in the study. As this was a retrospective observational study, no formal sample size was calculated. Overall survival and hepatic progression free survival (HPFS) from initial liver directed therapy (LDT) by DOTA and FDG-PETCT were identified.
Results: Amongst 44 patients, our hepatic progression free survival data ranged from 6-84 months with 2 year HPFS being 48% (21 patients with stable disease at 2 years) with a mean of 26 months. Overall survival ranged from 8-120 months with 3-year overall survival being 53% with a mean of 40 months.
Conclusions: Liver directed therapy in the form of ablation or transarterial therapy is an accepted method of treatment of unresectable hepatic metastases from neuroendocrine tumors. Our study shows that long-term palliation is possible using liver directed therapies, especially in those patients who have a predominantly hepatic disease; hence, it could be proposed as first-line non-surgical treatment in this subgroup of patients, and could be associated with somatostatin analogues when unable to control hormone related symptoms alone. In patients presenting with extra-hepatic lesions, it should be initially used in combination with systemic treatments. The need for repeat therapy and the interval between sessions should be tailored according to the patient response, tolerance, and need for palliation, so as to avoid unnecessary sessions.
